AI is rapidly advancing and shaking things up across a variety of industries, and marketing research is no exception. It’s clear that AI holds immense potential for analytic use in this field. Yet, we wanted to personally dig in to understand how AI stacks up against the claims. To gain a true picture of AI capabilities, MarketVision has been actively testing different AI analysis tools within our qualitative research practice to identify both their limits and potential to deliver value.  

Now that we have digested 2023 and are onboarding 2024, it’s a good time to assess where we are in the insights industry. After having an opportunity to connect with insights clients, research partners, and also peer companies at the Insights Association CEO Summit, several themes have emerged.

Unlocking the Hidden Links: Similarities Among Rare Diseases?

The criteria for what constitutes a rare disease differs from one country to another. For instance, the FDA Orphan Drug Act defines a rare disease as one that affects fewer than 200,000 people in the United States1. In the European Union, a rare disease is defined as one that affects no more than one person in 2,0002. Japan’s legal definition considers a disease rare if it affects fewer than 50,000 or about 1 in 2,500 people3. Given the lack of a universal definition, it raises the question: Could there be any similarities among rare diseases?

Replacing Flipcharts with Tablets

The Challenge: Illegible Flip Charts, Lots of Them…

In a world dominated by technology and automation, the financial services industry finds itself at a crossroads. The rise of FinTechs and digital advancements has undoubtedly increased efficiency and convenience, but it has also given rise to a growing concern – the loss of the human touch.

I just returned from the 2023 American Society of Clinical Oncology (ASCO) annual meeting, which I attended with 36,000 of my closest oncology friends. The meeting offered exciting science and meaningful clinical insights. What we understand about the biology and treatment of cancer is progressing at breakneck speed. It’s an exciting time to be in oncology.